Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Apalutamide

FDA-approved product (tablet, oral), marketed as Apalutamide, Erleada.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Apalutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Anti-androgens
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Apalutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Apalutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment

    NCT05717582 · start 2023-05-01

    Registered record
    Registry ID
    NCT05717582
    Conditions
    Metastatic Prostate Cancer; Castration-Sensitive Prostate Cancer
    Interventions
    apalutamide; androgen deprivation therapy; cytoreductive radical prostatectomy with/without pelvic lymph node dissection; metastasis-directed therapy with radiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2023-05-01
    Completion
    2026-12-31
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer; Castration-Sensitive Prostate Cancer
    Interventionapalutamide; androgen deprivation therapy; cytoreductive radical prostatectomy with/without pelvic lymph node dissection; metastasis-directed therapy with radiation
    PhasePhase 2
    Registry statusNot yet recruiting

  • Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

    NCT05751941 · start 2023-02-14

    Registered record
    Registry ID
    NCT05751941
    Conditions
    Prostate Cancer; Metastatic Prostate Cancer
    Interventions
    Abiraterone; Enzalutamide; Apalutamide; Sipuleucel-T
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-02-14
    Completion
    2026-12
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Metastatic Prostate Cancer
    InterventionAbiraterone; Enzalutamide; Apalutamide; Sipuleucel-T
    PhasePhase 2
    Registry statusActive not recruiting

  • Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

    NCT05701007 · start 2023-02-13

    Registered record
    Registry ID
    NCT05701007
    Conditions
    Metastatic Castration Sensitive Prostate Cancer (mCSPC); Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Interventions
    abiraterone; enzalutamide; docetaxel; apalutamide; cabazitaxel; Radium-223; Lutetium-177; degarelix; goserelin; leuprorelin; triptorelin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-02-13
    Completion
    2024-04-10
    Enrolment
    1,083

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration Sensitive Prostate Cancer (mCSPC); Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Interventionabiraterone; enzalutamide; docetaxel; apalutamide +7 more
    PhaseNot recorded
    Registry statusCompleted

  • Study of ORIC-944 in Patients With Metastatic Prostate Cancer

    NCT05413421 · start 2022-06-01

    Registered record
    Registry ID
    NCT05413421
    Conditions
    Metastatic Prostate Cancer
    Interventions
    ORIC-944; Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets; Apalutamide (Erleada™) 60 mg or 240 mg tablets; Darolutamide (Nubeqa®) 300 mg tablets; Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2022-06-01
    Completion
    2028-04
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer
    InterventionORIC-944; Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets; Apalutamide (Erleada™) 60 mg or 240 mg tablets; Darolutamide (Nubeqa®) 300 mg tablets +1 more
    PhasePhase 1
    Registry statusRecruiting

  • An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings

    NCT05362149 · start 2022-04-04

    Registered record
    Registry ID
    NCT05362149
    Conditions
    Non-metastatic Castration-resistant Prostate Cancer
    Interventions
    Darolutamide (Nubeqa, BAY1841788); Enzalutamide; Apalutamide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-04-04
    Completion
    2023-06-30
    Enrolment
    870

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-metastatic Castration-resistant Prostate Cancer
    InterventionDarolutamide (Nubeqa, BAY1841788); Enzalutamide; Apalutamide
    PhaseNot recorded
    Registry statusCompleted

  • A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer

    NCT05149131 · start 2022-01-17

    Registered record
    Registry ID
    NCT05149131
    Conditions
    Metastatic Castration-sensitive Prostate Cancer
    Interventions
    ADT (Eligard®*) with or without treatment intensification
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-01-17
    Completion
    2022-08-16
    Enrolment
    960

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-sensitive Prostate Cancer
    InterventionADT (Eligard®*) with or without treatment intensification
    PhaseNot recorded
    Registry statusCompleted

  • A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely

    NCT05202301 · start 2022-01-15

    Registered record
    Registry ID
    NCT05202301
    Conditions
    Prostate Cancer
    Interventions
    Darolutamide (Nubeqa, BAY1841788); Enzalutamide; Apalutamide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-01-15
    Completion
    2025-07-15
    Enrolment
    13,779

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDarolutamide (Nubeqa, BAY1841788); Enzalutamide; Apalutamide
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases

    NCT05740488 · start 2022-01-07

    Registered record
    Registry ID
    NCT05740488
    Conditions
    Prostate Cancer With ≤10 Bone Metastases
    Interventions
    Apalutamide; 89Sr; Luteinizing Hormone-Releasing Hormone Analog
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-01-07
    Completion
    2025-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer With ≤10 Bone Metastases
    InterventionApalutamide; 89Sr; Luteinizing Hormone-Releasing Hormone Analog
    PhaseNot applicable
    Registry statusUnknown

  • Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

    NCT04946370 · start 2021-08-12

    Registered record
    Registry ID
    NCT04946370
    Conditions
    Prostate Cancer
    Interventions
    225Ac-J591; Pembrolizumab; Androgen receptor inhibitor; 68Ga-PSMA-11
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2021-08-12
    Completion
    2029-12
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention225Ac-J591; Pembrolizumab; Androgen receptor inhibitor; 68Ga-PSMA-11
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

    NCT04729114 · start 2021-06-14

    Registered record
    Registry ID
    NCT04729114
    Conditions
    Prostate Cancer; Metastatic Castration Resistant Prostate Cancer; Metastatic Castration-sensitive Prostate Cancer
    Interventions
    PRL-02 injection; prednisone; dexamethasone; enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2021-06-14
    Completion
    2029-05-31
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Metastatic Castration Resistant Prostate Cancer; Metastatic Castration-sensitive Prostate Cancer
    InterventionPRL-02 injection; prednisone; dexamethasone; enzalutamide
    PhasePhase 1
    Registry statusRecruiting

  • ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer

    NCT04662580 · start 2021-05-03

    Registered record
    Registry ID
    NCT04662580
    Conditions
    Metastatic Prostate Cancer
    Interventions
    ARX517; Apalutamide; Abiraterone acetate; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2021-05-03
    Completion
    2026-12-31
    Enrolment
    183

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer
    InterventionARX517; Apalutamide; Abiraterone acetate; Prednisone
    PhasePhase 1
    Registry statusActive not recruiting

  • Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

    NCT03902951 · start 2021-03-17

    Registered record
    Registry ID
    NCT03902951
    Conditions
    Metastatic Prostate Adenocarcinoma; Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation; Recurrent Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Abiraterone Acetate; Apalutamide; Leuprolide Acetate; Quality-of-Life Assessment; Questionnaire Administration; Stereotactic Body Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-03-17
    Completion
    2028-01-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Adenocarcinoma; Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation; Recurrent Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
    InterventionAbiraterone Acetate; Apalutamide; Leuprolide Acetate; Quality-of-Life Assessment +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

    NCT04513717 · start 2021-01-21

    Registered record
    Registry ID
    NCT04513717
    Conditions
    Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    Interventions
    Apalutamide; Bicalutamide; Biospecimen Collection; Bone Scan; Buserelin; Computed Tomography; Degarelix; Flutamide; Goserelin; Histrelin; Leuprolide; Magnetic Resonance Elastography; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy; Relugolix; Triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-01-21
    Completion
    2038-12-31
    Enrolment
    2,753

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    InterventionApalutamide; Bicalutamide; Biospecimen Collection; Bone Scan +14 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

    NCT04585932 · start 2020-11-24

    Registered record
    Registry ID
    NCT04585932
    Conditions
    Biochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Oligometastatic Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Apalutamide; Degarelix; Leuprolide Acetate; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2020-11-24
    Completion
    2021-01-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Oligometastatic Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8 +2 more
    InterventionApalutamide; Degarelix; Leuprolide Acetate; Quality-of-Life Assessment +2 more
    PhasePhase 2
    Registry statusWithdrawn

  • Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    NCT04423211 · start 2020-10-08

    Registered record
    Registry ID
    NCT04423211
    Conditions
    Biochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
    Interventions
    3-Dimensional Conformal Radiation Therapy; Apalutamide; Computed Tomography; Degarelix; External Beam Radiation Therapy; Fluciclovine F18; Goserelin Acetate; Intensity-Modulated Proton Therapy; Intensity-Modulated Radiation Therapy; Leuprolide Acetate; Magnetic Resonance Imaging; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Relugolix; Stereotactic Body Radiation Therapy; Triptorelin; Volume Modulated Arc Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2020-10-08
    Completion
    2032-12-31
    Enrolment
    804

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
    Intervention3-Dimensional Conformal Radiation Therapy; Apalutamide; Computed Tomography; Degarelix +14 more
    PhasePhase 3
    Registry statusRecruiting